Jaguar Health, Inc. Announces Appointment of Melissa Yeager, J.D. as Senior Vice President, Regulatory Affairs and Quality Assurance
October 15, 2020 at 09:25 am
Share
Jaguar Health, Inc. and the company's wholly-owned subsidiary, Napo Pharmaceuticals Inc. (Napo), announced the appointment of Melissa Yeager, J.D., a successful executive leader with broad global regulatory affairs experience in the pharmaceutical, medical device and biotechnology fields, to the role of Senior Vice President, Regulatory Affairs Quality Assurance for both Jaguar and Napo. Ms. Yeager has held management positions in regulatory affairs, quality assurance and operations with Fortune 500 corporations such as Gilead Sciences and Becton Dickinson as well as specialized biotechnology ventures that include Alder BioPharmaceuticals, Breath Therapeutics, and Cardeas Pharma. Her major achievements include drug, device and combination product approvals in more than 40 countries. She has provided key leadership through all phases of product development and product approval efforts for multiple pharmaceutical products including Vyepti, Cayston and TOBI, the first approved inhalation antibiotic product. Ms. Yeager additionally has extensive experience in directing company compliance in accordance with international standards for laboratory testing and human clinical trial and manufacturing activities. She received her B.A. degree in Human Biology from Stanford University and her J.D. degree from Santa Clara University.
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.